Novo Nordisk, the maker of blockbuster diabetes and weight-loss drug Ozempic, has announced it will slash the drug’s U.S. price in half. The move comes after President Donald Trump’s administration ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Its amazing results have been hailed by Jeremy Clarkson, Whoopi Goldberg and The Telegraph’s own Allison Pearson, but from next month, the popular weight-loss drug Mounjaro could become inaccessible ...

Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.